GLP-1 Users Are Reporting Their Fingernails Detaching
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1 Users Are Reporting Their Fingernails Detaching" is generating significant coverage in the Health category, with 3 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include PharmaVoice and Medscape. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 33d ago.
Quick answers
Why is "GLP-1 Users Are Reporting Their Fingernails Detaching" trending?
Because 2 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- HHS’ need for R&D speed; weird GLP-1 side effects PharmaVoice · 36d ago
- GLP-1s Linked to Nail Disorders in New Study Medscape · 36d ago
- GLP-1s Linked to Nail Detachment and Other Disorders in New Study Medscape · 36d ago
Topics
Related trends
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Why Are People Acting So Weird in Restaurants?
Restaurant operators across North America are confronting a surge of AI-generated content and shifting diner behavior that is upending daily service.
Putin’s Soldiers Are Becoming Russia’s Next Deep State
Russian war veterans are transitioning into public administration, education, and political roles under Kremlin programs.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.